Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 16/20 | 0.68 |
| ▸ | CDK4 | P11802 | 15/20 | 0.68 |
| ▸ | EIF2AK2 | P19525 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4614032 | 0.87 | CDK2 (0.80) | CDK2CDK4EIF2AK2 | |
| SCHEMBL4613772 | 0.85 | CDK2 (0.77) | CDK2CDK4EIF2AK2 | |
| SCHEMBL4614634 | 0.81 | CDK2 (1.00) | CDK2CDK4EIF2AK2 | |
| SCHEMBL6911490 | 0.81 | CDK2 (0.80) | CDK2CDK4EIF2AK2 | |
| SCHEMBL4798545 | 0.79 | CDK2 (1.00) | CDK2CDK4 | |
| SCHEMBL29369233 | 0.79 | CDK2 (1.00) | CDK2CDK4 | |
| SCHEMBL4613610 | 0.78 | CDK2 (0.58) | CDK2CDK4 | |
| SCHEMBL4615866 | 0.76 | CDK2 (1.00) | CDK2CDK4EIF2AK2 | |
| SCHEMBL2087002 | 0.75 | CDK2 (0.72) | CDK2CDK4 | |
| SCHEMBL2086429 | 0.73 | CDK2 (0.69) | CDK2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572211-B1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES | CYCLACEL LTD (GB) | 2008-02-20 | — | — | EP | claimed |
| US-20050282843-A1 | Therapeutic applications of 2-substituted 4-heteroarylpyrimidines | CYCLACEL LIMITED (GB) | 2005-12-22 | — | — | US | claimed |
| EP-1572211-B1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES | CYCLACEL LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| EP-1572211-B1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES | CYCLACEL LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-20050282843-A1 | Therapeutic applications of 2-substituted 4-heteroarylpyrimidines | CYCLACEL LIMITED (GB) | 2005-12-22 | — | — | US | disclosed |
| EP-1572211-A1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLPYRIMIDINES | Cyclacel Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056368-A1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLRYRIMIDINES | CYCLACEL LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056368-A1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLRYRIMIDINES | CYCLACEL LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282843-A1 | Therapeutic applications of 2-substituted 4-heteroarylpyrimidines | HRH2, HRH3, CYTH3 | CDK2 810/4885CDK4 1254/4885EIF2AK2 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.